Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment... Read more.
AECOM selected as delivery partner for Eglinton Crosstown West Extension in Toronto
DALLAS–(BUSINESS WIRE)–AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, today announced it has been selected by Metrolinx to... Read more.
Chemours, DuPont, and Corteva Provide Update and Affirm Support for PFAS Settlement with U.S. Water Systems
WILMINGTON, Del.–(BUSINESS WIRE)–$CC–The Chemours Company (NYSE: CC), DuPont de Nemours, Inc. (NYSE: DD) and Corteva, Inc. (NYSE: CTVA) (the “Companies”)... Read more.
Kolibri Global Energy Inc. Provides 2023 Guidance Update and Operations Update
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Kolibri Global Energy Inc. (the “Company” or “KEI”) (TSX: KEI, NASDAQ: KGEI) is updating its estimated... Read more.
Tilly’s, Inc. Announces Participation in ICR Conference 2024
IRVINE, Calif.–(BUSINESS WIRE)–Tilly’s, Inc. (NYSE: TLYS) today announced that Ed Thomas, President and Chief Executive Officer, and Mike Henry, Executive... Read more.
2024 to Bring “Reputational Security” into Focus – Crisis Management Centre
KUALA LUMPUR, Malaysia–(BUSINESS WIRE)–#CrisisCommunication–The Crisis Management Centre foresees that 2024 will carry with it increased threats... Read more.
Spotify Technology S.A. to Announce Financial Results for Fourth Quarter 2023
NEW YORK–(BUSINESS WIRE)–Spotify Technology S.A. (NYSE: SPOT) will post its fourth quarter 2023 financial results and deck to shareholders on Tuesday,... Read more.
Best Buy Canada Launches Extra Hot Deals for Boxing Day – The Biggest Shopping Day of the Year
Boxing Day deals start online on December 24th at 6pm ET with new deals across all product categories VANCOUVER, British Columbia–(BUSINESS WIRE)–At... Read more.
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of BRUKINSA versus IMBRUVICA® (ibrutinib) in Relapsed... Read more.
Accenture Expands Digital Transformation Capabilities for Italy’s Public Sector with Acquisition of Customer Management IT and SirfinPA
MILAN & NEW YORK–(BUSINESS WIRE)–Accenture (NYSE: ACN) has signed an agreement to acquire Customer Management IT and SirfinPA, a pair of jointly-owned... Read more.